Study Title: KP405 First-in-Human Study in Parkinson's Disease
Intervention: KP405 (alpha-synuclein aggregation inhibitor)
Company: Kariya Pharmaceuticals
Phase: Phase 1
Status: Recruiting
KP405 is a small molecule alpha-synuclein aggregation inhibitor:
- Target: Alpha-synuclein (aSyn) protein misfolding and aggregation
- Mechanism: Prevents aSyn oligomerization and fibril formation
- Approach: Direct targeting of the aggregation pathway rather than downstream effects
Alpha-synuclein aggregation is the central pathological hallmark of Parkinson's disease:
- Lewy bodies contain aggregated aSyn
- Spreading of pathology correlates with disease progression
- Preventing aggregation may slow disease progression
- Early intervention may be most effective
KP405 represents a disease-modifying approach targeting the upstream pathological process.
- First-in-human study
- Single ascending dose / multiple ascending dose
- Safety and tolerability primary endpoints
- Biomarker assessments (alpha-synuclein species in CSF)
NCT06189170
- ClinicalTrials.gov: NCT06189170